Key Takeaways
- Morgan Stanley elevated ARWR to Overweight, setting a $100 price target versus the previous $78
- Plozasiran Phase 3 results for severe hypertriglyceridemia anticipated in the third quarter of 2026
- Bank of America increased its target, projecting approximately $3 billion in peak sales for the therapy
- Morgan Stanley’s analyst now forecasts $3.2 billion in peak revenue for plozasiran, up from $1.7 billion
- ARWR has gained 8.2% in 2026 and posted a stunning 481% return over the trailing year
Arrowhead Pharmaceuticals (ARWR) has delivered extraordinary returns to shareholders over the past twelve months, climbing 481%. The biotech stock extended its winning streak on Tuesday with a 3.9% gain, finishing at $71.92 following an analyst upgrade and increased price forecast from Morgan Stanley.
Arrowhead Pharmaceuticals, Inc., ARWR
The new $100 price objective suggests potential upside of roughly 39% from present trading levels. Michael Ulz, an analyst at Morgan Stanley, shifted his stance on the stock from Equal-weight to Overweight, pointing to forthcoming Phase 3 clinical trial results that he believes will “unlock a multibillion-dollar opportunity that remains underappreciated.”
The primary driver behind this optimism is plozasiran, the company’s flagship drug candidate currently in development for treating severe hypertriglyceridemia (SHTG) — a medical condition characterized by dangerously elevated triglyceride levels that significantly increase cardiovascular disease and pancreatitis risks.
The pivotal Phase 3 data release is scheduled for the third quarter of 2026. Drawing on previous trial outcomes and comparable patient studies, Ulz indicated his expectation for favorable results. A successful data readout could represent a watershed moment for Arrowhead.
Morgan Stanley isn’t operating in isolation with its bullish view. BofA similarly lifted its price forecast, estimating a peak commercial opportunity of roughly $3 billion for plozasiran in the SHTG indication — signaling that Wall Street analysts are gaining confidence in the drug’s revenue potential.
Ulz’s personal peak sales projection jumped from $1.7 billion to $3.2 billion. This substantial increase — nearly doubling the previous estimate — reflects strengthening conviction about the drug’s addressable market, particularly among high-risk patients vulnerable to pancreatitis complications.
Competitive Landscape With Ionis
Arrowhead faces competition in this therapeutic area. Ionis Pharmaceuticals (IONS) is pursuing the same SHTG patient population with its candidate olezarsen. Ulz noted that Ionis “has set the price” within this market segment.
Currently, olezarsen has received approval solely for familial chylomicronemia syndrome, though it carries Breakthrough Therapy designation. A supplemental filing is presently undergoing accelerated regulatory review, with an expected decision date of June 30.
Despite this competitive threat, Ulz maintains that the market can accommodate both therapies. He views plozasiran as having significant independent commercial potential, particularly within the pancreatitis patient segment.
Regulatory Submission and Development Pipeline
Arrowhead filed its inaugural New Drug Application for plozasiran during late 2024. This regulatory submission represented a pivotal milestone for the organization — signaling its evolution from a research-driven biotechnology firm toward a commercial-stage pharmaceutical company.
The organization has extensive experience in RNA interference technology. It obtained Roche’s RNAi business assets in 2011, followed by acquiring RNAi programs from Novartis in 2015. Johnson & Johnson’s Janssen division maintained a partnership with Arrowhead until 2023, when Janssen restructured its infectious disease and vaccine development efforts.
According to FactSet data, among the 12 analyst firms monitoring ARWR, 10 maintain Buy-equivalent ratings. Only two firms — Leerink Partners and Bernstein Research — assign Hold ratings to the stock.
ARWR shares have advanced 8.2% since the beginning of 2026. In contrast, Ionis has declined 6.2% year-to-date while posting a 156% gain over the past year.
Arrowhead currently commands a market capitalization of $9.94 billion.
